| Role of macrophage targeting in the antitumor activity of trabectedin G Germano, R Frapolli, C Belgiovine, A Anselmo, S Pesce, M Liguori, ... Cancer cell 23 (2), 249-262, 2013 | 928 | 2013 |
| Interleukin-12: biological properties and clinical application M Del Vecchio, E Bajetta, S Canova, MT Lotze, A Wesa, G Parmiani, ... Clinical Cancer Research 13 (16), 4677-4685, 2007 | 749 | 2007 |
| Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study A Necchi, A Anichini, D Raggi, A Briganti, S Massa, R Lucianò, ... Journal of Clinical Oncology 36 (34), 3353-3360, 2018 | 623 | 2018 |
| Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? G Parmiani, C Castelli, P Dalerba, R Mortarini, L Rivoltini, FM Marincola, ... Journal of the National Cancer Institute 94 (11), 805-818, 2002 | 551 | 2002 |
| NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo T Lakshmikanth, S Burke, TH Ali, S Kimpfler, F Ursini, L Ruggeri, ... The Journal of clinical investigation 119 (5), 1251-1263, 2009 | 410 | 2009 |
| Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade G Lo Russo, M Moro, M Sommariva, V Cancila, M Boeri, G Centonze, ... Clinical Cancer Research 25 (3), 989-999, 2019 | 398 | 2019 |
| Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction L Rivoltini, M Carrabba, V Huber, C Castelli, L Novellino, P Dalerba, ... Immunological reviews 188 (1), 97-113, 2002 | 378 | 2002 |
| Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. S Siena, M Di Nicola, M Bregni, R Mortarini, A Anichini, L Lombardi, ... Experimental hematology 23 (14), 1463-1471, 1995 | 299 | 1995 |
| Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. A Anichini, C Maccalli, R Mortarini, S Salvi, A Mazzocchi, P Squarcina, ... The Journal of experimental medicine 177 (4), 989-998, 1993 | 260 | 1993 |
| BRAF alterations are associated with complex mutational profiles in malignant melanoma M Daniotti, M Oggionni, T Ranzani, V Vallacchi, V Campi, D Di Stasi, ... Oncogene 23 (35), 5968-5977, 2004 | 246 | 2004 |
| An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide … A Anichini, A Molla, R Mortarini, G Tragni, I Bersani, M Di Nicola, ... The Journal of experimental medicine 190 (5), 651-668, 1999 | 228 | 1999 |
| Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. E Bajetta, M Del Vecchio, R Mortarini, R Nadeau, A Rakhit, L Rimassa, ... Clinical cancer research: an official journal of the American Association …, 1998 | 225 | 1998 |
| Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma R Mortarini, A Piris, A Maurichi, A Molla, I Bersani, A Bono, C Bartoli, ... Cancer Research 63 (10), 2535-2545, 2003 | 221 | 2003 |
| Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma M Sensi, G Nicolini, C Petti, I Bersani, F Lozupone, A Molla, C Vegetti, ... Oncogene 25 (24), 3357-3364, 2006 | 218 | 2006 |
| Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients L Passoni, L Longo, P Collini, AML Coluccia, F Bozzi, M Podda, ... Cancer research 69 (18), 7338-7346, 2009 | 215 | 2009 |
| Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand Y Kim, AM Lillo, SCJ Steiniger, Y Liu, C Ballatore, A Anichini, R Mortarini, ... Biochemistry 45 (31), 9434-9444, 2006 | 210 | 2006 |
| Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells E Yvon, M Del Vecchio, B Savoldo, V Hoyos, A Dutour, A Anichini, G Dotti, ... Clinical Cancer Research 15 (18), 5852-5860, 2009 | 179 | 2009 |
| Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma. A Anichini, R Mortarini, C Maccalli, P Squarcina, K Fleischhauer, ... Journal of immunology (Baltimore, Md.: 1950) 156 (1), 208-217, 1996 | 174 | 1996 |
| Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases A Garofalo, RGS Chirivi, C Foglieni, R Pigott, R Mortarini, I Martin-Padura, ... Cancer research 55 (2), 414-419, 1995 | 166 | 1995 |
| The α3β1 integrin is involved in melanoma cell migration and invasion A Melchiori, R Mortarini, S Carlone, PC Marchisio, A Anichini, DM Noonan, ... Experimental cell research 219 (1), 233-242, 1995 | 161 | 1995 |
Alessandro GianniIEO, University of Milan在 unimi.it 的电子邮件经过验证
